Immix Biopharma (IMMX) Corporate presentation summary

Unmet need in relapsed/refractory AL amyloidosis

• Over 30,000 U.S. patients with relapsed/refractory AL amyloidosis lack FDA-approved therapies, facing poor outcomes and limited options after frontline treatment failure.

• Standard second-line therapies yield only a 0-10% complete response rate, with most patients requiring additional treatment within a year.

NXC-201: Mechanism and innovation

• NXC-201 is a BCMA-targeted, sterically-optimized CAR-T cell therapy designed to eliminate pathogenic plasma cells and reduce toxic light chains.

• Proprietary modifications enhance cytotoxicity, reduce non-specific activation, and minimize cytokine release, aiming for improved safety and efficacy.

Clinical efficacy and safety

• In the U.S. NEXICART-2 trial, NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis, with rapid normalization of disease markers and 100% organ response in evaluable patients.

• Safety profile showed no grade 5 treatment-related adverse events, short CRS duration (median 1 day), and no neurotoxicity, supporting suitability for frail patients.